Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epcoritamab Plus Ibrutinib in Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
NCT06536049Phase 2Recruiting
- Start
- Apr 2025
- Primary completion
- Aug 2027
- Modality
- Antibody Conjugates, Small Molecules, Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of epcoritamab, ibrutinib in B-cell non-Hodgkin lymphoma. Started Apr 2025; status: recruiting.
02
Drugs
epcoritamabibrutinib
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT06536049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06536049.